Amarin Corp Plc (AMRN)

[Meowza]

Amarin parried an absurd patent construction largely unrelated to the incorrect reading of Kurabayashi's findings. Generics' arguments regarding prescriptions per the patent claim and how to properly compare Kurabayashi experiment arms are two largely unrelated issues.

The patent claim stuff is Judge Du ruling with Amarin that a practitioner need not conduct a clinical trial before each separate patient Rx. I.e. doctors can reference the previously reported difference between treatment and control arms instead of reinventing the experiment wheel.

The Kurabayashi nonsense is Judge Du copying and pasting generics' misleading statements about statistical significance re: EPA and controls' "differential effects" on ApoB. A certain recent blog post is conflating the patent and Kurabayashi discussions, hinging it on "well they both have the same words like controls and ApoB oh golly oh gosh oh my law is about interpretation baby".

The problem with law is some lawyers and legal theories depend on disingenuous equivocations.